US20100209517A1 - Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same - Google Patents

Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same Download PDF

Info

Publication number
US20100209517A1
US20100209517A1 US12706252 US70625210A US2010209517A1 US 20100209517 A1 US20100209517 A1 US 20100209517A1 US 12706252 US12706252 US 12706252 US 70625210 A US70625210 A US 70625210A US 2010209517 A1 US2010209517 A1 US 2010209517A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
composition according
anti
pharmaceutical composition
pharmaceutically acceptable
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12706252
Inventor
Ninh On
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boots Co PLC
Original Assignee
Boots Co PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine

Abstract

The present invention provides a method for eliciting an onset hastened analgesic and anti-inflammatory response and combating nausea in acute migraine attacks. This method comprises administering a pharmaceutical composition comprising more than one active ingredient, wherein said more than one active ingredient consist essentially of:
    • (i) domperidone or an analogue thereof in an amount sufficient to hasten the onset of the analgesic and anti-inflammatory response and to combat nausea in an acute migraine attack, and
    • (ii) a NSAID, a pharmaceutically acceptable salt thereof or a pure (−) or pure (+) optical isomeric form thereof in an analgesically and anti-inflammatory effective amount, wherein said NSAID is selected from the group consisting of proprionic acid derivatives, acetic acid derivatives, fenamic acid derivatives, biphenylcarboxylic acid derivatives and oxicams.

Description

    CROSS REFERENCE TO RELATED APPLICATION
  • This application is a continuation of U.S. Ser. No. 10/922,828, filed Aug. 23, 2004, which is a continuation of Ser. No. 09/956,816, filed Sep. 21, 2001, which is a continuation of Ser. No. 09/492,164, filed Jan. 27, 2000, now U.S. Pat. No. 6,319,514, issued Nov. 20, 2001, which in turn is a continuation of Ser. No. 08/859,185, filed May 20, 1997, now abandoned, which claims priority to U.K. Application No. 9613410.1, filed Jun. 26, 1996.
  • BACKGROUND TO THE ART
  • The current means of combating migraine attacks include simple analgesics such as aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDS) and paracetamol, taken at the earliest signs of an attack [1, 2, 3]. Aspirin, paracetamol and phenacetin have long been among the most commonly used members of the NSAIDS class. Amongst the newer NSAIDS are ibuprofen, ketoprofen, mefenamic acid, diflunisal, naproxen and piroxicam. The most widely used NSAIDS available over the counter that have fewer gastro intestinal side effects than aspirin are paracetamol and ibuprofen.
  • Combined preparations of paracetamol or aspirin with an anti-emetic agent such as buclizine or metoclopramide, have been used to alleviate the nausea symptoms that often accompanied a migraine attack. Commercially, they are available as Migraleve Duo®, Paramax®, Migravess®. Narcotic analgesics such as codeine have also been employed together with NSAIDS to obtain synergistic analgesia, for example Migraleve Yellow®, co-codamol.
  • Gastric stasis, commonly present in migraine[4], causes the poor absorption of the analgesics. Dispersible and effervescent formulations have been used in an attempt to overcome this [4]. Metoclopramide, an anti-emetic, also relieves gastric stasis which has been found useful counteracting the reduced analgesic effects of paracetamol in migraine attacks [1, 4, 5].
  • Attacks who do not respond to analgesics may be treated with ergot preparations such as ergotamine tartrate. Newer alternatives to ergot compounds for acute migraine are the selective serotonin 5HT1 agonist, for example Sumatriptan® [6, 7] . Recent trials reported that oral 100 mg sumatriptan to be as effective as aspirin 900 mg plus 10 mg metoclopramide for initial attacks and more effective in subsequent attacks [8].
  • The use of metoclopramide combined with either paracetamol, or aspirin has already been disclosed. Domperidone is a dopamine antagonist but is less likely than metoclopramide to produce extra pyramidal side effects since it does not cross the blood brain barrier. It stimulates gastro-intestinal mobility and is used in the management of nausea and vomiting. The activity of domperidone on the gastro intestinal mobility could enhance the rate of absorption of the analgesics. In Cephalagia 13 (2), 124-7 (1993), the safety and efficacy of separately administered domperidone in combination with paracetamol in the treatment of acute attack of migraine was demonstrated. The method of making a film coated tablet containing paracetamol and domperidone is disclosed in WO95/22974.
  • As far as the inventor knows, the art has never suggested that domperidone either be added to selected NSAIDS, which differ substantially in chemical structure from paracetamol; or be added to selected NSAIDS together with selected narcotic analgesic drugs. Also, the prior art does not suggest the use of any two-component composition of a selected NSAID and domperidone; and three-component of a selected NSAID, a selected narcotic analgesic and domperidone to hasten the analgesic response and ‘to manage nausea symptoms in migraine attacks.
  • DETAILED DESCRIPTION OF THE INVENTION
  • The NSAIDS for use in the compositions and methods of the present invention can be selected from the following categories:
      • 1) the propionic acid derivatives;
      • 2) the acetic acid derivatives;
      • 3) the fenamic acid derivatives;
      • 4) the biphenylcarboxyclic acid derivatives;
      • 5) the oxicams.
  • All the contemplated compounds can be used at appropriate dosage levels for the purpose in the composition of the present invention. The compounds in groups 1 to 4 typically contain a carboxylic acid function; however, those acids are sometimes administered in the form of their pharmaceutically acceptable salts, e.g. sodium salts.
  • The propionic acid derivatives for use herein include, but are not limited to, ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, prapoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, fluprofen, and bucloxic acid. Structurally related propionic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group. Presently preferred members of the propionic acid group include ibuprofen, naproxen, flurbiprofen, fenoprofen, ketoprofen and fenbufen.
  • The acetic acid derivatives for use herein include, but not limited to, indomethacin, sulindac, tolmetin, zomepirac, diclofenac, fenchlofenac, alchlofenac, ibufenac, isoxepac, furofenac, tiopinac, zidometacin, acemetacin, fentiazac, clidanac and oxipinac. Structurally related acetic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group. Presently, preferred members of the acetic acid group include tolmetin sodium, zomepinac sodium, sulindac and indomethacin.
  • The fenamic acid derivatives for use herein include, but are not limited to, mefenamic acid, meclofenamic acid, flufenamic acid, niflumic acid and tolfenamic acid. Structurally related fenamic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to encompassed by this group. Presently, preferred members of the fenamic acid group include mefenemic acid and meclofenamate sodium (meclofenamic acid, sodium salt).
  • The biphenylcarboxylic acid derivatives for use herein include, but are not limited to, diflunisal and flufenisal. Structurally related biphenylcarboxylic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group. Preferred members of this group are diflunisal and flufenisal.
  • The oxicams for use herein include, but are not limited to, piroxicam, sudoxicam, isoxicam. Structurally related oxicams having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group. A preferred member of this group is piroxicam.
  • The narcotic analgesics for use in the present invention are orally active narcotic agonists. Suitable agonist-antagonist for use herein include orally analgesically active antagonists of the nalorphine type, notably pentazocine; and orally analgesically active antagonists of the morphine type, notably buprenorphine. Another suitable agonist-antagonist is meptazinol. Suitable narcotic agonists for use herein include orally analgesically active members of the morphine group, notably codeine, oxycodone, dihydrocodeine, dextropropoxyphene, papaveretum and tramadol. In many instances, the narcotic analgesics for use herein are administered in the forms of their pharmaceutically acceptable acid addition salts, e.g. codeine sulphate, codeine phosphate, dihydrocodeine tartrate and tramadol hydrochloride. Structurally related analogues to the aforementioned compounds having similar analgesic property are also intended to be encompassed by this group.
  • For compounds (NSAIDS or narcotic analgesics) which have optically active centre(s), the invention refers to the racemate as well as the pure (−) or (+) optical isomeric forms.
  • The domperidone or its analogues used herein is intended to encompass not only domperidone as the anhydrous powered but any salt or derivatives or any compounded mixture thereof which is non toxic, pharmaceutically acceptable and which has gastric motility stimulating activity to enhance absorption of the co-administered analgesic(s) in gastric stasis and anti-emetic property. Presently, the preferred salt of domperidone is maleate.
  • The term “selected NSAID” as used herein is intended to mean any non-narcotic analgesic/nonsteroidal anti-inflammatory compound within one of the five structural categories indicated hereinabove. Similarly, the term “selected narcotic analgesic” as used herein is intended to mean any orally analgesically active narcotic analgesic, be it an orally active narcotic agonist having oral analgesic activity. The terms “selected NSAID” and “selected narcotic analgesic” are used for the sake of simplicity in the discussion which follows.
  • When a selected NSAID or NSAID plus a selected narcotic analgesic is combined with domperidone in accord with the present invention, the following results may be produced:
      • The analgesic/anti-inflammatory effect of the selected NSAID as a single active or NSAID plus a selected narcotic analgesic can be brought on more quickly;
      • the nausea symptom experienced in acute migraine attacks can be averted or alleviated.
  • For patients suffering migraine headache, the time from administration of medication to the onset of effective relief is clearly of paramount importance. The hastening of the onset analgesia by combining domperidone with a selected NSAID or a selected NSAID plus a selected narcotic analgesic according to the present invention is therefore can be very significant.
  • The precise amount of NSAID or narcotic analgesic drug for use in the present compositions will vary depending, for example, on the specific drug chosen, the condition for which the drug is administered. Generally speaking, the selected NSAID or narcotic analgesic can be employed in any amount known to be an effective analgesic and anti-inflammatory amount.
  • Typical effective analgesic amounts of presently preferred NSAIDs/narcotic analgesic for use in unit dose compositions of the invention can be found in the British National Formulary, American Hospital Formulary, Martindale Extra Pharmacopoeia, e.g. 50-600 mg Ibuprofen. In a two component composition of a selected NSAID and domperidone and a three component composition of a selected NSAID, a selected narcotic analgesic and domperidone, the daily analgesic dose for each analgesic will generally not exceed their daily analgesic dosages. The ratio of a selected NSAID to a selected narcotic analgesic may vary depending on the particular drugs selected and the required analgesic response.
  • While the compositions of the invention are preferably for oral use, they may also be formulated for and administered by other methods which are known for administering analgesics, e.g. suppositories. Also, the preferred dosage levels mentioned earlier are used in adults; pediatric compositions would contain proportionally less of the active ingredients.
  • The compositions of the present invention can be conveniently administered by any route of administration suitable for the selected NSAID and/or selected narcotic analgesic component, e.g. oral or rectal. Preferably, the combination is formulated with any suitable nontoxic pharmaceutically acceptable-inert carrier material. Such carrier materials are well known to those skilled in the art.
  • In a typical preparation for oral administration, e.g. tablet or capsule, the selected NSAID in an effective analgesic/anti-inflammatory amount and domperidone in an amount sufficient to hasten its onset and/or to control nausea and vomiting; or the selective NSAID in an effective analgesic/anti-inflammatory amount together with a selected narcotic analgesic in an amount sufficient to enhance the analgesic response and domperidone in an amount sufficient to hasten its onset and/or to control nausea and vomiting; are combined with any oral nontoxic pharmaceutically acceptable inert carrier such as lactose, starch (pharmaceutical grade), dicalcium phosphate, calcium sulphate, kaolin, mannitol and powder sugar.
  • Additionally, when required, suitable binders, lubricants, disintegrating agents, colouring agents and coating agents can also be included. Typical binders include starch, gelatine, sugars such as sucrose, molasses and lactose, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone, polyethylene glycol, ethylcellulose and waxes. Typical lubricants for use in the dosage forms can include, without limitation, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine and polyethylene glycol. Suitable disintegrators can include, without limitation, starch, methylcellulose, agar, bentonite, cellulose, wood products, alginic acid, guar gum, citris pulp, carboxymethylcellulose and sodium lauryl sulphate. Sweetening and flavouring agents and preservatives may be included, particularly when a liquid dosage form is formulated, e.g. syrup, suspension and elixir. When the dosage form is a capsule, it may contain, in addition to the above type, a liquid carrier such as fatty oil. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit.
  • REFERENCES
    • 1) Atkinson R, Appenzeller O (1984). Headache. Postgrad Med J; 60: 841-846.
    • 2) Diamond S., Milistein E (1988). Current concepts of migraine therapy. J. Clin Pharmacol; 28: 193-199.
    • 3) Anonymous (1984). Drugs for migraine. Med Lett Drugs Ther; 26: 95-96.
    • 4) Clough C (1989). Treating migraine. Br Med J; 299: 141-142.
    • 5) Peatfield R (1983). Migraine: Current concepts of pathogenesis and treatment. Drugs; 26: 364-371.
    • 6) Pearce J M S (1991). Sumatriptan in migraine. Br Med J; 303: 1941.
    • 7) Fullerton T, Gengo F M (1992). Sumatriptan: a selective 5-hydroxytryptamine receptor agonist for the acute treatment of migraine. Ann Pharmacother; 26: 800-808.
    • 8) The oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group (1992). A study to compare oral sumatriptan with oral Aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol;. 32:177-184.

Claims (41)

  1. 1. A method for treating acute migraine attacks by eliciting an onset hastened analgesic and anti-inflammatory response and combating nausea in a subject in need of an analgesic, anti-inflammatory and anti-nausea response, comprising administering a pharmaceutical composition comprising effective amounts of more than one active ingredient to said subject, wherein said more than one active ingredient consists essentially of:
    (i) domperidone or an analogue thereof in an amount sufficient to hasten the onset of the analgesic and anti-inflammatory response and to combat nausea in an acute migraine attack, and
    (ii) a NSAID, a pharmaceutically acceptable salt thereof or a pure (−) or (+) optical isomeric form thereof in an analgesically and anti-inflammatory effective amount, wherein said NSAID is selected from the group consisting of ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, prapoprofen, miroprofen, 20 tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, flurprofen and bucloxic acid.
  2. 2. A method according to claim 1, wherein the domperidone analogue is domperidone maleate.
  3. 3. A pharmaceutical composition for treating acute migraine attacks which elicits an onset hastened analgesic and anti-inflammatory response and combats nausea, comprising effective amounts of more than one active ingredient wherein said more than one active ingredient consist essentially of:
    (i) domperidone or an analogue thereof in an amount sufficient to hasten the onset of the analgesic and anti-inflammatory response and to combat nausea in an acute migraine attack, and
    (ii) ibuprofen, a pharmaceutically acceptable salt thereof or a pure (−) or (+) optical isomeric form thereof in an analgesically and anti-inflammatory effective amount.
  4. 4. A method according to claim 1, wherein said more than one active ingredient consist of domperidone maleate and ibuprofen.
  5. 5. A pharmaceutical composition for treating acute migraine attacks by eliciting an onset hastened analgesic and anti-inflammatory response comprising effective amounts of more than one active ingredient, wherein said more than one active ingredient consist essentially of:
    (i) domperidone or an analogue thereof in an amount sufficient to hasten the onset of the analgesic and anti-inflammatory response and to combat nausea in an acute migraine attack, and
    (ii) a NSAID, a pharmaceutically acceptable salt thereof or a pure (−) or (+) optical isomeric form thereof in an analgesically and anti-inflammatory effective amount, wherein said NSAID is selected from the group consisting of ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, prapoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, flurprofen and bucloxic acid.
  6. 6. A pharmaceutical composition according to claim 5, wherein the NSAID is ibuprofen.
  7. 7. A pharmaceutical composition according to claim 5, wherein the domperidone analogue is domperidone maleate.
  8. 8. A pharmaceutical composition according to claim 5, wherein said more than one active ingredient consist of domperidone maleate and ibuprofen.
  9. 9. A pharmaceutical composition according to claim 5, wherein said composition is formulated for oral administration.
  10. 10. A pharmaceutical composition according to claim 5, wherein said composition is formulated as a tablet or capsule with the addition of a suitable pharmaceutically acceptable carrier.
  11. 11. A pharmaceutical composition according to claim 10, wherein said composition is formulated as a dispersible or effervescent dosage form with the addition of a suitable pharmaceutically acceptable carrier.
  12. 12. A pharmaceutical composition according to claim 10, wherein said composition is in a microencapsulated dosage form with the addition of a suitable pharmaceutically acceptable carrier.
  13. 13. A pharmaceutical composition according to claim 5, said composition is formulated as granules for oral administration with the addition of a suitable pharmaceutically acceptable carrier
  14. 14. A pharmaceutical composition according to claim 5, wherein said composition is formulated for rectal administration.
  15. 15. A pharmaceutical composition according to claim 14, wherein said composition is formulated as a suppository with the addition of a suitable pharmaceutically acceptable carrier.
  16. 16. A pharmaceutical composition according to claim 5, wherein said composition is formulated as an enema or rectal solution.
  17. 17. A pharmaceutical composition for treating acute migraine attacks by eliciting an onset hastened analgesic and anti-inflammatory response and combating nausea in a subject in need of an analgesic, anti-inflammatory and anti-nausea response, comprising effective amounts of more than one active ingredient, wherein said more than one active ingredient consist essentially of:
    (i) domperidone or an analogue thereof in an amount sufficient to hasten the onset of the analgesic and anti-inflammatory response and to combat nausea in an acute migraine attack, and
    (ii) a NSAID, a pharmaceutically acceptable salt thereof or a pure (−) or (+) optical isomeric form thereof in an analgesically and anti-inflammatory effective amount, wherein said NSAID is selected from the group consisting of ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, prapoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, flurprofen and bucloxic acid.
  18. 18. A pharmaceutical composition according to claim 17, wherein the NSAID is ibuprofen.
  19. 19. A composition according to claim 17, wherein the domperidone analogue is domperidone maleate.
  20. 20. A pharmaceutical composition according to claim 17, wherein said more than one active ingredient consist of domperidone maleate and ibuprofen.
  21. 21. A composition according to claim 18, wherein said composition is formulated for oral administration.
  22. 22. A composition according to claim 21, wherein said composition is formulated as a tablet or capsule with the addition of a suitable pharmaceutically acceptable carrier.
  23. 23. A composition according to claim 21, wherein said composition is formulated as a dispersible or effervescent dosage form with the addition of a suitable pharmaceutically acceptable carrier.
  24. 24. A composition according to claim 21, wherein said composition is in microencapsulated dosage form with the addition of a suitable pharmaceutically acceptable carrier.
  25. 25. A composition according to claim 21, wherein said composition is formulated as granules for oral administration.
  26. 26. A composition according to claim 17, wherein said composition is formulated for rectal administration.
  27. 27. A composition according to claim 17, wherein said composition is formulated as a suppository with the addition of a suitable pharmaceutically acceptable carrier.
  28. 28. A composition according to claim 17, wherein said composition is formulated as an enema or rectal solution with the addition of a suitable pharmaceutically acceptable carrier.
  29. 29. A pharmaceutical composition for combating nausea in acute migraine attacks comprising more than one active ingredient, wherein said more than one active ingredient consists essentially of:
    (i) domperidone or an analogue thereof in an amount sufficient to hasten the onset of the analgesic and anti-inflammatory response and to combat nausea in an acute migraine attack, and
    (ii) a NSAID, a pharmaceutically acceptable salt thereof or a pure (−) or (+) optical isomeric form thereof in an analgesically and anti-inflammatory effective amount, wherein said NSAID is selected from the group consisting of ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, prapoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, flurprofen and bucloxic acid.
  30. 30. A pharmaceutical composition according to claim 29, wherein the NSAID is ibuprofen.
  31. 31. A pharmaceutical composition according to claim 30, wherein said more than one active ingredient consist of domperidone maleate and ibuprofen.
  32. 32. A pharmaceutical composition according to claim 29, further comprising a suitable pharmaceutically acceptable carrier.
  33. 33. A pharmaceutical composition according to claim 29, wherein said composition is formulated for oral administration.
  34. 34. A pharmaceutical composition according to claim 33, wherein said composition is formulated as a tablet or capsule with the addition of a suitable pharmaceutically acceptable carrier.
  35. 35. A pharmaceutical composition according to claim 33, wherein said composition is formulated as a dispersible or effervescent dosage form with the addition of a suitable pharmaceutically acceptable carrier.
  36. 36. A pharmaceutical composition according to claim 33, wherein said composition is in microencapsulated dosage form with the addition of a suitable pharmaceutically acceptable carrier.
  37. 37. A pharmaceutical composition according to claim 33, wherein said composition is formulated as granules for oral administration.
  38. 38. A pharmaceutical composition according to claim 29, wherein said composition is formulated for rectal administration.
  39. 39. A pharmaceutical composition according to claim 29, wherein said composition is formulated as a suppository with the addition of a suitable pharmaceutically acceptable carrier.
  40. 40. A pharmaceutical composition according to claim 38, wherein said composition is formulated as an enema or rectal solution with the addition of a suitable pharmaceutically acceptable carrier.
  41. 41. A pharmaceutical composition for treating acute migraine attacks by eliciting an onset hastened analgesic and anti-inflammatory response comprising effective amounts of only two pharmaceutically active ingredients, wherein:
    (i) said first pharmaceutical active ingredient comprises domperidone or an analogue thereof in an amount sufficient to hasten the onset of the analgesic and anti-inflammatory response and to combat nausea in an acute migraine attack, and
    (ii) said second pharmaceutical active ingredient comprises a NSAID, a pharmaceutically acceptable salt thereof or a pure (−) or (+) optical isomeric form thereof in an analgesically and anti-inflammatory effective amount, wherein said NSAID is selected from the group consisting of ibuprofen, naproxen, benoxaprofen, flurbiprofen, fenoprofen, fenbufen, ketoprofen, indoprofen, pirprofen, carprofen, oxaprozin, prapoprofen, miroprofen, tioxaprofen, suprofen, alminoprofen, tiaprofenic acid, flurprofen and bucloxic acid.
US12706252 1996-05-24 2010-02-16 Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same Abandoned US20100209517A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GB9613410A GB2313309B (en) 1996-05-24 1996-06-26 Pharmaceutical compositions comprising a nonsteroidal anti-inflammatory drug and domperidone in the treatment of migraine
GB9613410.1 1996-06-26
US85918597 true 1997-05-20 1997-05-20
US09492164 US6319514B1 (en) 1996-06-26 2000-01-27 Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same
US09956816 US20020025971A1 (en) 1996-06-26 2001-09-21 Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same
US10922828 US20050026961A1 (en) 1996-06-26 2004-08-23 Analgesic and anti-inflammatory compositions comprising domperidone and methods of using the same
US12706252 US20100209517A1 (en) 1996-06-26 2010-02-16 Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12706252 US20100209517A1 (en) 1996-06-26 2010-02-16 Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same
US13299440 US20120064152A1 (en) 1996-06-26 2011-11-18 Analgesic and Anti-Inflammatory Compositions Comprising Domperidone and Methods of Using Same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10922828 Continuation US20050026961A1 (en) 1996-05-24 2004-08-23 Analgesic and anti-inflammatory compositions comprising domperidone and methods of using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13299440 Continuation US20120064152A1 (en) 1996-05-24 2011-11-18 Analgesic and Anti-Inflammatory Compositions Comprising Domperidone and Methods of Using Same

Publications (1)

Publication Number Publication Date
US20100209517A1 true true US20100209517A1 (en) 2010-08-19

Family

ID=10795927

Family Applications (5)

Application Number Title Priority Date Filing Date
US09492164 Expired - Fee Related US6319514B1 (en) 1996-05-24 2000-01-27 Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same
US09956816 Abandoned US20020025971A1 (en) 1996-05-24 2001-09-21 Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same
US10922828 Abandoned US20050026961A1 (en) 1996-05-24 2004-08-23 Analgesic and anti-inflammatory compositions comprising domperidone and methods of using the same
US12706252 Abandoned US20100209517A1 (en) 1996-05-24 2010-02-16 Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same
US13299440 Abandoned US20120064152A1 (en) 1996-05-24 2011-11-18 Analgesic and Anti-Inflammatory Compositions Comprising Domperidone and Methods of Using Same

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US09492164 Expired - Fee Related US6319514B1 (en) 1996-05-24 2000-01-27 Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same
US09956816 Abandoned US20020025971A1 (en) 1996-05-24 2001-09-21 Analgesic and anti-inflammatory compositions comprising domperidone and methods of using same
US10922828 Abandoned US20050026961A1 (en) 1996-05-24 2004-08-23 Analgesic and anti-inflammatory compositions comprising domperidone and methods of using the same

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13299440 Abandoned US20120064152A1 (en) 1996-05-24 2011-11-18 Analgesic and Anti-Inflammatory Compositions Comprising Domperidone and Methods of Using Same

Country Status (2)

Country Link
US (5) US6319514B1 (en)
GB (1) GB9710767D0 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9710767D0 (en) * 1996-06-26 1997-07-23 On Ninh Analgesic and anti-inflamatory compositions comprising domperidone and methods of using same
GB9816899D0 (en) * 1998-08-05 1998-09-30 Boots Co Plc Therapeutic agents
US8173164B2 (en) * 1999-06-17 2012-05-08 Gruenenthal Gmbh Oral administration forms for administering a fixed tramadol and diclofenac combination
WO2008006099A3 (en) * 2006-07-07 2008-02-21 Suzanne Hendrix Treatment of psychiatric disorders
EP2142176A1 (en) * 2007-04-26 2010-01-13 Craig A. Aronchick Compositions and methods for transmucosal delivery of domperidone

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3160562A (en) * 1962-06-27 1964-12-08 Sandoz Ltd Composition containing ergotamine, caffeine and hydantoin derivatives for cephalalgia
US4693621A (en) * 1984-01-25 1987-09-15 Tokyo Electric Co., Ltd. Paper loading device of printer
US4985459A (en) * 1984-02-08 1991-01-15 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US5053429A (en) * 1988-04-08 1991-10-01 The Lithox Corporation, Inc. Treating inflammatory pain with methionine
US5215758A (en) * 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5273759A (en) * 1990-06-27 1993-12-28 Lipopharm Inc. Method and composition for treating the migraine complex
US5460828A (en) * 1993-01-28 1995-10-24 Recordati S.A., Chemical And Pharmaceutical Company Process for the preparation of microgranules suitable for suspension in fluids
US5587179A (en) * 1992-01-13 1996-12-24 Gerhard Gergeky Pharmaceutical formulation in the form of an effervescent and/or disintegrating tablet or of instant granulate, and process for their preparation
US5814339A (en) * 1994-02-28 1998-09-29 Janssen Pharmaceutica, N.V. Film coated tablet of paracetamol and domperidone
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US5985874A (en) * 1998-05-11 1999-11-16 Merck Sharp & Dohme Ltd. Substituted morpholine derivative and its use as a therapeutic agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160562A (en) * 1977-12-05 1979-07-10 Giovanni Crestetto Automotive bumper
US4698621A (en) * 1984-09-25 1987-10-06 Masot Oscar V Circuit breaker panels with alarm system
GB8816187D0 (en) * 1988-07-07 1988-08-10 Glaxo Group Ltd Medicaments
GB9710767D0 (en) * 1996-06-26 1997-07-23 On Ninh Analgesic and anti-inflamatory compositions comprising domperidone and methods of using same

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3160562A (en) * 1962-06-27 1964-12-08 Sandoz Ltd Composition containing ergotamine, caffeine and hydantoin derivatives for cephalalgia
US4693621A (en) * 1984-01-25 1987-09-15 Tokyo Electric Co., Ltd. Paper loading device of printer
US4985459A (en) * 1984-02-08 1991-01-15 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same
US5053429A (en) * 1988-04-08 1991-10-01 The Lithox Corporation, Inc. Treating inflammatory pain with methionine
US5273759A (en) * 1990-06-27 1993-12-28 Lipopharm Inc. Method and composition for treating the migraine complex
US5215758A (en) * 1991-09-11 1993-06-01 Euroceltique, S.A. Controlled release matrix suppository for pharmaceuticals
US5587179A (en) * 1992-01-13 1996-12-24 Gerhard Gergeky Pharmaceutical formulation in the form of an effervescent and/or disintegrating tablet or of instant granulate, and process for their preparation
US5460828A (en) * 1993-01-28 1995-10-24 Recordati S.A., Chemical And Pharmaceutical Company Process for the preparation of microgranules suitable for suspension in fluids
US5814339A (en) * 1994-02-28 1998-09-29 Janssen Pharmaceutica, N.V. Film coated tablet of paracetamol and domperidone
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US5985874A (en) * 1998-05-11 1999-11-16 Merck Sharp & Dohme Ltd. Substituted morpholine derivative and its use as a therapeutic agent

Also Published As

Publication number Publication date Type
US6319514B1 (en) 2001-11-20 grant
US20050026961A1 (en) 2005-02-03 application
GB9710767D0 (en) 1997-07-23 grant
US20020025971A1 (en) 2002-02-28 application
US20120064152A1 (en) 2012-03-15 application

Similar Documents

Publication Publication Date Title
US7645767B2 (en) Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
US6552031B1 (en) Synergistic analgesic combination of oxycodone and rofecoxib
Gibson Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl
US20050232986A1 (en) Dosage form containing promethazine and another drug
US5945416A (en) Method for treating pain
US20020156133A1 (en) Oral administration forms for administering a fixed tramadol and diclofenac combination
US6326374B1 (en) Compositions comprising GABA analogs and caffeine
US5196436A (en) Dextromethorphan antitussive compositions
Camu et al. Pharmacology of systemic analgesics
US20010008889A1 (en) Anticonvulsant containing composition for treating neuropathic pain
US6426338B1 (en) Therapy for constipation
Bamigbade et al. The clinical use of tramadol hydrochloride
US6221377B1 (en) Administration media for analgesic, anti-inflammatory and anti-pyretic drugs containing nitrous oxide and pharmaceutical compositions containing such media and drugs
US6060499A (en) Anti-migraine methods and compositions using 5-HT agonists with long-acting NSAIDs
Mathisen et al. Lack of pre‐emptive analgesic effect of (R)‐ketamine in laparoscopic cholecystectomy
US20060287284A1 (en) Pharmaceutical composition combining tenatoprazole and an anti-inflamatory agent
US7030162B2 (en) Treatment of migraine headache
US4749722A (en) Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4783465A (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
US4975426A (en) Cough/cold mixtures comprising non-sedating antihistamine drugs
WO1998050044A1 (en) Composition and method combining an antidepressant with an nmda receptor antagonist, for treating neuropathic pain
US4571400A (en) Dihydrocodeine/ibuprofen pharmaceutical compositions and method
US20080031950A1 (en) Novel anelgesic combination
US5025019A (en) Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4829064A (en) Cough/cold mixtures comprising non-sedating antihistamine drugs